ReviewNeural regeneration research2016
Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery.
Review in Neural regeneration research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Hormonal regulatory networks in spinal cord injury: mechanistic insights, crosstalk, and therapeutic innovations.Frontiers in endocrinology · 2025Review
- Dopaminergic REST is implicated in the tamoxifen-induced neuroprotection against manganese toxicity in female mice.Frontiers in pharmacology · 2025Article
- Neuroimmune modulating and energy supporting nanozyme-mimic scaffold synergistically promotes axon regeneration after spinal cord injury.Journal of nanobiotechnology · 2024Article
- Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review.International journal of molecular sciences · 2024Review
- Administration of Tamoxifen Can Regulate Changes in Gene Expression during the Acute Phase of Traumatic Spinal Cord Injury.Current issues in molecular biology · 2023Article
- Degenerative Cervical Myelopathy: Insights into Its Pathobiology and Molecular Mechanisms.Journal of clinical medicine · 2021Review
- Developmental Biology in Central America, the northern region of South America and the Caribbean.The International journal of developmental biology · 2021Review
- Estrogen improved the regeneration of axons after subcortical axon injury via regulation of PI3K/Akt/CDK5/Tau pathway.Brain and behavior · 2020Article
- Posttraumatic stress disorder and breast cancer: Risk factors and the role of inflammation and endocrine function.Cancer · 2020Review
- Delayed short-term tamoxifen treatment does not promote remyelination or neuron sparing after spinal cord injury.PloS one · 2020Article
- Eriodictyol corrects functional recovery and myelin loss in SCI rats.Translational neuroscience · 2020Article
- Coenzyme Q10 Regulation of Apoptosis and Oxidative Stress in HOxidative medicine and cellular longevity · 2019Article
- Article
- Lithium promotes recovery of neurological function after spinal cord injury by inducing autophagy.Neural regeneration research · 2018Article
- Efficacy of tamoxifen for the treatment of severe equine asthma.Journal of veterinary internal medicine · 2018Article
- 17β-estradiol and tamoxifen protect mice from manganese-induced dopaminergic neurotoxicity.Neurotoxicology · 2018Article
- Continuous tamoxifen delivery improves locomotor recovery 6h after spinal cord injury by neuronal and glial mechanisms in male rats.Experimental neurology · 2018Article
- Neuroprotective mechanisms of rutin for spinal cord injury through anti-oxidation and anti-inflammation and inhibition of p38 mitogen activated protein kinase pathway.Neural regeneration research · 2018Article
- Nanofiber Scaffolds as Drug Delivery Systems to Bridge Spinal Cord Injury.Pharmaceuticals (Basel, Switzerland) · 2017Review
- Aldehyde dehydrogenase 2 overexpression inhibits neuronal apoptosis after spinal cord ischemia/reperfusion injury.Neural regeneration research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Spinal cord injury (SCI) is a condition without a cure, affecting sensory and/or motor functions. The physical trauma to the spinal cord initiates a cascade of molecular and cellular events that generates a non-permissive environment for cell survival and axonal regeneration. Among these complex set of events are damage of the blood-brain barrier, edema formation, inflammation, oxidative stress, demyelination, reactive gliosis and apoptosis. The multiple events activated after SCI require a multi-active drug that could target most of these events and produce a permissive environment for cell survival, regeneration, vascular reorganization and synaptic formation. Tamoxifen, a selective estrogen receptor modulator, is an FDA approved drug with several neuroprotective properties that should be considered for the treatment of this devastating condition. Various investigators using different animal models and injury parameters have demonstrated the beneficial effects of this drug to improve functional locomotor recovery after SCI. Results suggest that the mechanism of action of Tamoxifen administration is to modulate anti-oxidant, anti-inflammatory and anti-gliotic responses. A gap of knowledge exists regarding the sex differences in response to Tamoxifen and the therapeutic window available to administer this treatment. In addition, the effects of Tamoxifen in axonal outgrowth or synapse formation needs to be investigated. This review will address some of the mechanisms activated by Tamoxifen after SCI and the results recently published by investigators in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.